Filing summary
Important identity discrepancy: The supplied filing is StemCells, Inc.’s Form 10-Q for the quarter ended September 30, 2012—not a Microbot Medical Inc. filing. The summary below describes the filing text provided; verify the issuer and filing before relying on it.
Business context and reporting period
StemCells described itself as a biopharmaceutical company developing stem-cell therapeutics and research tools. The report covers the three and nine months ended September 30, 2012, compared with the same periods in 2011. Its primary therapeutic focus was HuCNS-SC cells, in clinical development for several conditions; research-product sales and licensing provided limited revenue.
Financial performance and liquidity
| Metric | Q3 2012 | Nine months 2012 |
|---|---|---|
| Revenue | $264,000 | $1.157 million |
| Gross profit | $192,000 | $949,000 |
| Gross profit as a share of revenue | 72.8% | 82.0% |
| Operating loss | $5.077 million | $15.753 million |
| Net loss | $16.337 million | $25.733 million |
| Net loss per share, basic and diluted | $0.54 | $0.99 |
| Operating cash used | Not separately provided for the quarter | $14.950 million |
Q3 revenue increased 18% year over year; nine-month revenue increased 70%. Product sales rose 11% and 33%, respectively, while licensing, grants and other revenue rose 47% and 190%. The nine-month increase in the latter category was attributed primarily to licensing fees from genOway.
At September 30, cash and cash equivalents were $15.713 million and current marketable securities were $6.032 million. Current assets were $23.244 million versus current liabilities of $4.053 million. Total liabilities were $20.434 million, including $381,000 of bonds payable and a $14.483 million warrant liability. The warrant liability is a fair-value accounting liability, not conventional borrowings. Stockholders’ equity was $9.224 million.
For the nine months, operating cash use was $14.950 million, investing cash use was $2.768 million, and financing provided $20.131 million. Financing included net common-stock proceeds of $16.197 million and warrant-exercise proceeds of $4.154 million. Cash increased by $2.414 million from year-end 2011.
Material changes versus the prior comparable period
- Operating expenses fell 17% in Q3 and 22% for the nine-month period, mainly reflecting lower R&D costs, reduced personnel and facilities costs, and lower external clinical and preclinical service costs.
- R&D expense declined 23% in Q3 and 26% over nine months; SG&A declined 6% and 10%, respectively.
- Net loss increased substantially: Q3 loss rose from $4.334 million to $16.337 million, and nine-month loss from $14.117 million to $25.733 million. The principal factor was the change in fair value of warrant liabilities: a $11.239 million Q3 expense in 2012 versus $1.697 million of income in Q3 2011, and $9.975 million of expense for nine months 2012 versus $6.500 million of income in 2011. The filing identifies this as a model-based fair-value change.
- Weighted-average shares outstanding increased to 30.2 million for Q3 and 26.0 million for the nine-month period, from 14.0 million and 13.8 million, respectively, in 2011.
Outlook, risks and unusual items
- Management expected continued operating losses and substantial R&D spending for the foreseeable future, and said it did not expect profitability in the next several years. It stated that significant additional capital was needed and warned that inability to obtain financing could force program reductions or, if cash reserves were exhausted, bankruptcy proceedings.
- CIRM approved two awards of up to $20 million each for preclinical development programs in cervical spinal cord injury and Alzheimer’s disease, with the aim of filing an IND for each within up to four years. At September 30, no funds had been disbursed; funding was expected to take the form of forgivable loans subject to agreed terms.
- Clinical commentary included preliminary PMD trial findings in four patients and interim six-month spinal-cord-injury findings in three patients. The filing reported favorable safety observations and sensory-function gains in two of the three spinal-cord-injury patients; these are early-stage results, not evidence of established efficacy.
- After quarter-end, the company reported approximately $3.714 million of gross proceeds from October stock sales and approximately $963,000 expected from warrant exercises. These transactions increased or were expected to increase shares outstanding.
- Contractual obligations totaled $18.403 million, predominantly operating leases, including a long-term Newark, California lease. Rhode Island facility wind-down expenses were $1.318 million at quarter-end; estimates depend on occupancy and other assumptions.
- Neuralstem patent litigation remained ongoing, with discovery underway and a trial anticipated in 2013. The company said risk factors had not materially changed from its 2011 Form 10-K. Management reported disclosure controls and procedures were effective.
Important facts for investors to verify
- Confirm the filing issuer: this source identifies StemCells, Inc., not Microbot Medical Inc.
- Review the warrant-liability valuation and its large effect on reported net loss; distinguish accounting remeasurement from operating cash burn.
- Assess cash runway against the reported operating cash use, continuing development costs, and management’s stated need for additional capital.
- Check the final CIRM award terms, disbursement conditions, and whether any funding was received after the reporting date.
- Track dilution from equity sales and warrant exercises, and verify the post-quarter transactions and updated share count.
- Follow clinical-trial progress, regulatory decisions, and the outcome and timing of the Neuralstem litigation.